Teva Pharmaceutical Industries (TEVA) Short-Term Debt issuances (2017 - 2023)

Teva Pharmaceutical Industries has disclosed Short-Term Debt issuances across 6 years of filings, most recently posting $700.0 million for Q3 2023.

• Quarterly Short-Term Debt issuances changed N/A year-over-year to $700.0 million in Q3 2023, while the trailing twelve-month figure through Dec 2024 was $700.0 million (down 22.22% YoY) and the FY2023 annual result came in at $700.0 million, changed N/A from the prior year.
• Short-Term Debt issuances rose to $700.0 million in Q3 2023, from $200.0 million in the prior quarter.
• Over five years, Short-Term Debt issuances peaked at $700.0 million in Q3 2023 and troughed at -$1.0 million in Q1 2019.
• A 4-year average of $245.6 million and a median of $200.0 million in 2021 frame the typical range for Short-Term Debt issuances.
• Annual changes were most pronounced in 2019 — Short-Term Debt issuances soared 9900.0% — and 2021, when it plunged 37.3%.
• Tracing TEVA's Short-Term Debt issuances over 4 years: stood at $404.0 million in 2019, then fell by 21.04% to $319.0 million in 2020, then plunged by 37.3% to $200.0 million in 2021, then soared by 250.0% to $700.0 million in 2023.
• Business Quant data shows TEVA's Short-Term Debt issuances at $700.0 million in Q3 2023, $200.0 million in Q4 2021, and $319.0 million in Q4 2020.